TargetMol

Q-VD-OPH

Product Code:
 
TAR-T0282
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T0282-1mg1mg£108.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0282-5mg5mg£140.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0282-1mL1 mL * 10 mM (in DMSO)£149.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0282-10mg10mg£189.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0282-25mg25mg£261.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0282-50mg50mg£366.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0282-100mg100mg£510.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Q-VD-OPha is a pan-caspase inhibitor with potent antiapoptotic properties.
CAS:
1135695-98-5
Formula:
C26H25F2N3O6
Molecular Weight:
513.498
Pathway:
Apoptosis; Proteases/Proteasome; Microbiology/Virology
Purity:
0.978
SMILES:
CC(C)[C@H](NC(=O)c1ccc2ccccc2n1)C(=O)N[C@@H](CC(O)=O)C(=O)COc1c(F)cccc1F
Target:
Caspase; HIV Protease

References

1. Mischak R. ICN Bioconcepts. 2002, 8, 1?5. 2. Caserta TM, et al. Apoptosis. 2003, 8(4), 345-352. 3. Melnikov VY, et al. J Clin Invest. 2002, 110(8), 1083-1091. 4. DeBiasi RL, et al. J Virol. 2004, 78(20), 11040-11050. 5. Rohn TT, et al. Int J Clin Exp Med. 2009, 2(4), 300-308.